Anzeige
Mehr »
Lynx Broker
Login
Mittwoch, 11.12.2019 Börsentäglich über 12.000 News von 620 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

NASDAQ Biotech 

WKN:  ISIN:  
Markt oder Branche auswählen:

Aktuelle News zu Aktien im NASDAQ Biotech

  • 24 h
  • 7 Tage
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache:  Alle DE EN
LeserMedien
17:08Can Sanofi and Regeneron's Dupixent steal half of a $21B eczema market? Not so fast: analyst1
16:58Seattle Genetics: A Prudent Growth Story1
16:46Aurelius bearish on Neurocrine Biosciences15
16:42SABCS: Seattle Genetics hails 'stunning' tucatinib breast cancer data1
16:42SABCS: MacroGenics' margetuximab posts OS gains in specific metastatic breast cancer patients1
16:10MacroGenics, Inc.: MacroGenics Presents Results from the SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer at the San ...3
16:10Sage Therapeutics up 9% on insider buys2
14:58Synlogic up 6% premarket on advancement of PKU candidate-
14:58Kiniksa Pharma up 7% premarket on Kite collaboration-
14:47ProQR Therapeutics N.V. - 6-K, Report of foreign issuer-
14:34Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma93 -- Phase 2 study will Examine the Effect of Mavrilimumab on the Clinical Profile of Yescarta -- Kite, a Gilead Company (Nasdaq: GILD), and Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) ("Kiniksa")...
► Artikel lesen
14:34Kiniksa Pharmaceuticals, Ltd.: Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta and ...-
14:17Healthpeak Amends & Extends Lease With Amgen in San Francisco-
13:42Dermira secures FDA fast track status for lebrikizumab in atopic dermatitis1
13:35BIOCRYST PHARMACEUTICALS INC - 8-K, Current Report-
13:34BioCryst files U.S. application for berotralstat for HAE2
13:22Is Rigel Pharmaceuticals Stock a Buy?1
13:22BioCryst submits NDA for BCX73531
13:17PROTEOSTASIS THERAPEUTICS, INC. - 8-K, Current Report7
13:10Rocket Pharma down 7% premarket on pricing equity offering-
Seite:  Weiter >>